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Abstract 
 
A 64-year-old man ingested about 60 ml 2% of topical 
minoxidil solution in order tomake his hair grow faster. 
Twelve hours after ingestion he was brought to the Uni-
versity Clinic of Toxicology with severe hypotension, 
tachycardia, chest pain and subendocardial ischemia. 
ECG showed diffuse T-wave inversion and depressed ST 
segments. He was also oligoanuric at admission. In spite 
of the intensive hydration with crystalloidsolutions and 
intravenous dopamine administrationthat resulted in par-
tial hemodynamic improvement and resolution of the 
ECG changes, kidneyfailure occurred. After two hymo-
dialysis sessions, urea and creatinine levels returned to 
normal and rebound hypertension appeared. The patient 
was discharged after 12 days of hospitalization in a good 
condition. Topical minoxidilsolution is formulation used 
for treatment of androgenic alopecia. If orally ingested it 
leads to severe hypotension, acute coronary syndrome, 
compensatory tachycardia and acute kidneyfailure. Emer-
gency therapeutic approach is a precondition for su-
ccessful outcome. 
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Introduction 
 
Minoxidil is a known antihypertensive drug, which has 
recently been approved for treatment of androgenic alo-
pecia. It can be found on the market as 5% and 2% 
solution. Sixty ml of 2% solution contains about 1,200 
mg of minoxidil, which is approximately 12 times greater 
than the maximum recommended daily dose for contro-
lling hypertension. Correlation between minoxidil in 
 
 
 
 
gestion and development ofsubendocardial ischemia, 
hemodynamic impairment and acute kidney failure 
(AKF) will be discussed in this paper. 
 
Case report 
 
A 64-year-old man with no prior history of kidney 
failure and cardiologic diseases was brought as an emer-
gency case into the University Clinic of Toxicology 12 
hourspost-ingestion of 60 ml 2% of minoxidil solution 
(Pilfud, Bosnalijek). He ingested the solution in order 
to achieve rapid therapeutic effects. He denied use of 
alcohol or other medications, but said he suffered from 
a moderate hypertension. On admission he was conscious, 
orientedto time and place, afebrile, eupneic. His pulse 
was 110/min, and blood pressure was 60/20 mmHg. The 
patient experienced chest pain, epigastric discomfort, 
weakness and malaise. ECG showed tachycardia and 
signs of subendocardial ischemia. Therapy was initiated 
with resuscitation with 2.5 literof physiological solution 
given in the first 7 hours, but the patient was anuric. Fo-
llowing administration of 8 mcg/kg/min dopamine the 
blood pressure increased to 90/60 mmHgat 12 hours 
after admission, and at 24 hours it reached and remained 
at 100/70 mmHg in the first three days. The dose of 
dopamine was gradually reduced to 2 mcg/kg and dis-
continued after 48 hours. Diuresis was 100/300/700 
ml/24 hours on the first/second/third day, respectively, 
but the values of degradation products increased. The  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
105 
 
 
 
 
Table 1.The most characteristic laboratory and clinical parameters 
day hours CK CK-MB CK-MB% Na K urea creatinine diuresis/24h TA 
1 09 346 19 5.49 136 4.2 11.1 310 100 60/20 
 21 992 14 1.41 141 4.0 15.1 356  90/60 
2 09 1098 52 4.74 138 4.8 28.6 601 250 100/70 
 21 720 45 6.25 136 4.5            
31.9       
659    90/50 
3 09 324 22 6.79 134 4.4 34.6 625 700 90/50 
 21    128 4.3 36.5 757*  100/60 
4 09 200 14 7.00 134 4.5 21.6 270* 2000 150/85 
7 09 170 10 5.88 139 4.8 14.9 124 6400 180/100 
10 09 84 8 9.52 140 4.4 4.5 74 9100 200/130 
 21         170/110 
12 09 75 6 8.00 142 4.5 5.0 82 3000 140/90 
 21         130/80 
Values of CK, CK-MB, urea, creatinine are expressed in mmol/l, dieresis in ml/24h, blood pressure in mm Hg.  *hemodialysis 
 
patient underwent two hemodialysis sessions on the 
third and fourth day, which resulted in a polyuric pha-
se and decrease of urea and creatinine. Blood pressure 
started to increase and since the fourth day until the 
end of the hospital stay ranged from 150/85 to 200/130 
mmHg (rebound hypertension). 
Laboratory analysis showed leukocytosis, increase of 
CK (creatine kinase) and CK-MB, which did not surpass 
10% of the CK value, and troponine was negative. Urea 
and creatininepeaked at36.5 mmol/l and 757 mmol/l, 
respectively, on the third day and returned to normal 
on the 10th day. The remaining laboratory findings were 
unspecific (Table 1). 
The first day ECG revealed diffusely inverted T-waves 
with depressed ST segments in V2-V6. These changes 
withdrew and ECG stabilized on the third day (Figure 
1, Figure 2). 
 
 
 Fig.1. First day ECG  
 
 
  Fig. 2. Third day ECG 
 
Discussion 
 
Minoxidil, which was originally used for treatment of 
hypertension, recently has been approved for treatment 
of male pattern baldness [1]. Adverse effects of mi-
noxidil local application are rare and minor. Most co-
mmonly it can cause itching and irritation on the affect-
ted area and other dermatologic complications and minor 
systemic effects due to its small resorption. The systemic 
application of minoxidil is associated with more se-
rious complications. 
Minoxidil is activated in the liver and its action isto relax 
vascular smooth muscle by opening cell surface pota-
ssium channels causing an efflux of potassium, hyper-
polarization and relaxation of smooth muscle cells. 
Minoxidilproduces systemic hypotension by a direct 
arteriolar vasodilatation and is associated with a reflex  
 
 
increase in cardiac output and myocardial contractility 
mediated by the sympathetic nervous system. Maximal 
concentration in the blood is achieved 1 hour after oral 
administration, but due to delay of active metabolic for-
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mation, the maximal therapeutic effect appears much 
later. The serum half-life is 3 to 4 hours, but the effect 
can last 24 hours or longer [2]. Minoxidil is eliminated 
mainly by hepatic metabolism. 
There are reports thatminoxidil does not cause hypotension 
in normotensive individuals [3]. However, many authors 
report prolonged hypotension post-ingestion, which lasts 
two to four days after admission to the hospital [4,5]. 
Various cardiovascular manifestations resulting from 
different doses of minoxidil have been reported. Lower 
doses produce hypotension and successive increase in 
doses leads to tachycardia and myocardial ischemia. 
This tachycardia and resultant myocardial ischemia are 
probably a compensatory mechanism for severe hypoten-
sion. These cases are treated with combination of crys-
talloids, dopamine [6] and phenylephrine infusion [7] 
guided by the cardiovascular parameters. 
The greater the contractility, the more oxygen the myo-
cardium consumes. Increased heart rate (HR) leads to 
increased myocardial O2 consumption.   
In our patient, in addition to prolonged hypotension 
and tachycardia coronary syndrome developed along 
with reverse ECG changes and negative CK-MB and 
troponine. Subendocardial ischemia is believed to be 
caused by an increased myocardial oxygen demanddue 
to secondary catecholamine overload that increases 
myocardial contractilityand decreasedcoronary perfusion 
that is due to tachycardia and hypotension acute mino-
xidil intoxication. Similar transitory ECG changes when 
larger doses of minoxidil (about 3 grams) had been given 
were described by other authors [8,9]. Some authors have 
presented development of nontransmural infarction as 
a result of ingestion of similar amount of minoxidil so-
lution, associated with pleural effusion and good res-
ponse to conservative treatment [7]. 
Besides coronary syndrome, the patient developed AKF 
that did not respond to the conservative treatment, but 
hemodialysis was required for returning the degradation 
products to normal values. In our patient the cause for 
kidney failure was dishemodynamicand was probably 
a result of delayed hospitalization (12 hours post-inges-
tion) and prolonged kidney hypoperfusion. In other case 
reports a smaller degree of oliguria was registered as 
well as a smaller increase in degradation products with 
more rapid response to drug treatment as a result of 
the urgent hospitalization (two hours post-ingestion at 
the most) [5,7,9]. There is a lack of literature on mi-
noxidil direct nephrotoxicity that results in decreased 
kidney function in a state of acute overdosage. There-
fore, we assume there was a preranal failure in our pa-
tient, which was caused by hemodynamic insufficien-
cy and suffered renal hypoxia. 
The so-called rebound hypertension was registered in 
our patient, which appeared on the 4
th
 day of the hospital 
stay, that is, following hemodialysis and establishment 
of diuresis. 
By definition rebound hypertension is an increase in 
blood pressure in response to stopping or reducing high 
blood pressure medication. Severe cases can result in a 
very large increase in blood pressure which requires 
prompt treatment to avoid complications such as organ 
damage. Hypertension in our patient was a result of 
blood pressure establishing without therapy, when mi-
noxidil, which is dialyzable, was completely eliminated 
and kidney function was improved. Althoughprazosin 
was included in the therapy on the seventh day, peak va-
lue was reached on the 10
th
 day of hospitalization (200/130 
mmHg), and it returned to normal until the discharge 
day by dose adjustmentof prazosin in the therapy. There 
are no case reports in the literature presenting with 
rebound hypertension after minoxidil intoxication. 
However, this phenomenon has been described in chil-
dren treated with several hypertensive drugs after discon-
tinuation of minoxidil therapy due to the development 
ofhypertrichosis. Rebound hypertension was manifested 
with hypertensive encephalopathy in those children in 
whom minoxidil was withdrawn rapidly. The occurrence 
ofrebound hypertension correlated well with the cumu-
lative dose of minoxidil and the rapidity with which 
minoxidil was withdrawn [10]. Thus, we think this phe-
nomenon can appear also in patients intoxicated with 
minoxidil, who had a history of hypertension and can 
be an additional risk factor for onset of other co-mor-
bidities if it is not expected and not treated. 
In summary, we have presented a case of severe poiso-
ning after ingestion of 2% of topical minoxidil solution. 
This is the first case in our clinical practice, which was 
manifested with severe hypotension, tachycardia, sub-
endocardial ischemia, AKF and rebound hypertension. 
As the use and availability of these solutions for local 
application is increasing, a greater awarenessof systemic 
toxic effect of minoxidil is also necessary as well as 
immediate and adequate treatment. 
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